Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements (Details)

v3.22.2.2
Collaboration and License Agreements (Details)
1 Months Ended 9 Months Ended
Mar. 10, 2020
USD ($)
Jul. 31, 2021
USD ($)
shares
Sep. 30, 2022
USD ($)
Country
Milestone
Sep. 30, 2021
USD ($)
BioSense License and Assignments Agreement [Member]        
Collaboration and License Agreement [Abstract]        
Upfront payment received $ 1,650,000      
Milestone payment achieved for performance obligation, recorded as collaboration revenue       $ 100,000
Maximum amount of payments receivable for development, regulatory and commercial milestones     $ 84,500,000  
Milestone payments received     0  
BioSense License and Assignments Agreement [Member] | Rexahn [Member]        
Collaboration and License Agreement [Abstract]        
Upfront payment received $ 1,550,000      
Processa License Agreement [Member]        
Collaboration and License Agreement [Abstract]        
Upfront payment received   $ 200,000    
Milestone payments received     $ 0  
Upfront payment received in common shares (in shares) | shares   44,689    
Upfront payment received in common shares   $ 289,000    
Period of restriction from selling common stock     1 year  
Number of times sales milestone payments | Milestone     1  
Percentage of milestone payments eligible to receive on sub-license agreement     32.00%  
Number of countries | Country     1  
Milestone period to administer drug clinical trial of licensed product on first patient     3 years  
Milestone period to administer drug clinical trial of licensed product on first patient for second indication     5 years  
Period of opportunity to cure breach of agreement     120 days  
Period of prior written notice to be served for termination of agreements     120 days